Repeat PSMA-PET Detects Disease in 56% of Negative-Scan Recurrent Prostate Cancer Cases, Altering Management in 50%
Registry data show repeat PSMA-PET changes care in half of initially negative recurrent prostate cancer cases. The observational design confirms detection rates but cannot prove outcome improvement. Randomized trials with survival endpoints are required next.
Next steps require randomized evaluation of repeat PSMA-PET timing against PSA kinetics alone, paired with long-term endpoints. Integration with emerging blood-based biomarkers could further refine patient selection and reduce unnecessary radiation exposure.
Metser et al.: Within 24 months, at least two additional North American registries will report progression-free survival stratified by repeat PSMA-PET findings, with oligometastatic cohorts showing >20% absolute PFS difference versus observation.
Sources (3)
- [1]Primary Source(https://jnm.snmjournals.org/content/early/2026/07/01/jnumed.126.272204)
- [2]Supporting Source(https://www.nejm.org/doi/10.1056/NEJMoa1915937)
- [3]Supporting Source(https://pubmed.ncbi.nlm.nih.gov/35294888/)